Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer

Within this single institution retrospective analysis, patients with advanced NSCLC and a KRAS activating mutation exhibited inferior responses to cytotoxic chemotherapy and decreased survival compared to patients with advanced NSCLC and no KRAS mutation.